Total chemical synthesis was used to prepare the mirror image (D-protein) form of the angiogenic protein vascular endothelial growth factor (VEGF-A). Phage display against D-VEGF-A was used to screen designed libraries based on a unique small protein scaffold in order to identify a high affinity ligand. Chemically synthesized Dand L-forms of the protein ligand showed reciprocal chiral specificity in surface plasmon resonance binding experiments: The L-protein ligand bound only to D-VEGF-A, whereas the D-protein ligand bound only to L-VEGF-A. The D-protein ligand, but not the L-protein ligand, inhibited the binding of natural VEGF 165 to the VEGFR1 receptor. Racemic protein crystallography was used to determine the high resolution X-ray structure of the heterochiral complex consisting of fD-protein antagonist þ L-protein form of VEGF-Ag. Crystallization of a racemic mixture of these synthetic proteins in appropriate stoichiometry gave a racemic protein complex of more than 73 kDa containing six synthetic protein molecules. The structure of the complex was determined to a resolution of 1.6 Å. Detailed analysis of the interaction between the D-protein antagonist and the VEGF-A protein molecule showed that the binding interface comprised a contact surface area of approximately 800 Å 2 in accord with our design objectives, and that the D-protein antagonist binds to the same region of VEGF-A that interacts with VEGFR1-domain 2.
O ne of the most remarkable aspects of the natural world is the homochirality of the protein macromolecules found in living systems (1) . All protein molecules found in nature contain ribosomally translated polypeptide chains that are comprised exclusively of L-amino acids and the achiral amino acid glycine. Starting about 20 years ago, chemists and biochemists became interested in the properties of unnatural mirror image D-protein molecules; i.e., proteins with polypeptide chains of the same sequence as natural proteins, but made from D-amino acids and glycine. In pioneering work, Zawadzke and Berg showed that a racemic mixture of the enantiomeric forms of the small protein rubredoxin crystallized in a centrosymmetric space group and that the folded protein molecules were mirror images of one another (2) . More recently, racemic crystallography of chemically synthesized protein enantiomers has been used to facilitate the crystallization of recalcitrant proteins and to solve protein structures that had not previously been determined by X-ray crystallography (3) (4) (5) (6) (7) .
Chirality, the handedness of molecules (8) , is fundamental to biological interactions. This aspect of chirality was first systematically demonstrated by Emil Fischer, who-based on his studies of sugar stereochemistry-formulated the 'lock and key' principle of enzyme action on chiral substrate molecules (9) . Since then, it has been repeatedly demonstrated that natural proteins preferentially bind to only one enantiomer of chiral small molecule ligands. The principles of molecular chirality dictate that the inverse also be true-i.e., that the mirror image form of a natural protein molecule will preferentially bind to the opposite enantiomer of a chiral ligand (10) . Chirality is believed to be of particular importance in protein-protein interactions-it is considered a self-evident conclusion of symmetry arguments that the enantiomer of a protein ligand will not bind to the same natural protein target, and that enantiomeric forms of a protein-(protein ligand) pair will have the same affinity for one another. Nonetheless, experimental demonstration of this principle may be instructive.
In 1996, Peter Kim and his colleagues at the Whitehead Institute at MITused peptide phage display against a D-protein target as a way to systematically develop D-peptide ligands of natural proteins (11) . As originally conceived, this 'mirror image (peptide) phage display' method involved the chemical synthesis of the mirror image form of a natural protein molecule, after which peptide phage libraries were screened to identify L-peptide ligands to the D-protein. Then, chemical synthesis was used to make the corresponding D-peptide ligand, which obligately bound with the same affinity to the natural protein target. Such D-peptide ligands would be resistant to proteolytic digestion in vivo, and for that reason they have excited a great deal of interest. Although mirror image phage display has been used in a number of academic studies (12) (13) (14) , it has not yet led to the development of D-peptides as therapeutics.
We set out to apply the mirror image phage display approach to esigned libraries of a unique protein scaffold in order to develop high affinity D-protein antagonist(s) for biologically active protein targets. A properly engineered D-protein molecule would have near optimal properties as a therapeutic: A small D-protein can be produced by chemical manufacture, will resist proteolytic degradation, and is expected to be nonimmunogenic (15) . Further, it should be possible to engineer a small D-protein to have affinity and specificity similar to that of antibodies for a therapeutic target molecule. Development of improved antagonists of growth factor activity is an important current objective in medicinal chemistry. The angiogenic factor vascular endothelial growth factor (VEGF-A) is the target of engineered monoclonal antibodies that inhibit angiogenesis by interfering with the interaction of VEGF-A with its receptors (16) , and several of these engineered antibodies have become important human therapeutics.
The objective of the work reported here was to develop a D-protein ligand that binds to VEGF-A and acts as an antagonist of VEGF-A binding to its receptor. Our target was the covalent homodimer VEGF protein molecule; this form of VEGF-A retains full biological activity and was used in the development of the monoclonal antibodies bevacizumab and ranibizumab (16) (17) (18) . Here we report the total chemical synthesis of the mirror image D-VEGF-A protein molecule, the use of mirror image protein phage display of designed libraries based on a unique protein scaffold, and the consequent generation of a specific D-protein ligand for VEGF-A that blocks binding to the VEGFR1 receptor. The high resolution X-ray structure of the fD-Protein Antagonist plusVEGF-Ag protein complex was determined by racemic protein crystallography.
Results and Discussion
Chemical Synthesis of D-VEGF-A. The essential first step was to prepare the mirror image form of the VEGF target protein. Recently we reported the total synthesis of the natural enantiomer of this form of the VEGF-A protein molecule with full biological activity (19) . Here, we used total synthesis enabled by modern chemical ligation methods to prepare D-VEGF-A, the mirror image form of VEGF-A (Fig. 1) . Three unprotected synthetic peptide segments were condensed by native chemical ligation (20) in a series of 'one pot' reactions; i.e., without purification of intermediate products (Fig. 1A) . The purified synthetic 102 residue D-polypeptide chain (Fig. 1B) was folded in the presence of a redox couple, with concomitant formation of native disulfide bonds, to give the D-protein molecule (Fig. 1C) . Synthetic D-VEGF-A was characterized by electrospray mass spectrometry, and had an observed mass (23,849.3 AE 0.7 Da) in agreement with the expected mass (23,849.1 Da, average isotope composition) for the covalent homodimer containing eight disulfide bonds (19) . Synthetic D-VEGF-A was crystallized, and X-ray diffraction data was acquired to a resolution of 1.9 Å.
The structure was solved by molecular replacement, using inverted coordinates of the previously reported VEGF-A structure (PDB code: 3QTK) as a search model. A portion of the resulting 2Fo-Fc electron density map is shown in SI Appendix, Fig. S1C , and the structure of synthetic D-VEGF-A is shown in Fig. 1D . The chemically synthesized D-VEGF-A had a structure that was the mirror image of natural recombinant VEGF-A (17, 18) , within experimental uncertainty.
A Protein Ligand for D-VEGF-A We used the B1 domain of streptococcal protein G (GB1) (21) as a scaffold for the development of small protein ligands. Natural protein GB1 is a well studied small protein that folds stably and reversibly and that binds to the Fc region of immunoglobulins with high affinity (22) . GB1 consists of a polypeptide chain of 56 amino acids, small enough to be made by total chemical synthesis and yet large enough to provide a sufficient surface area for a strong binding interface between the D-protein antagonist and its target protein. While there are several miniprotein scaffolds that have been developed (23) , they typically do not present enough solvent exposed surface area to match the affinity and specificity of antibodies. We displayed GB1 on M13 filamentous phage as a fusion with coat protein p3, and with an N-terminal FLAG tag. A library of GB1 mutants was constructed from 15 contiguous residues on the surface of the protein, within the region spanning residues 21-41 and with the insertion of one or two additional residues between positions 41 and 42 ( Fig. 1E) , in order to generate a binding interface with an area comparable to that of antibodies. The selected residues were randomized by a KHT codon, which allows the amino acids Y, A, D, S, F, and V at each position. This codon was chosen because one of us (Sidhu) has previously shown that minimalist libraries of aromatic amino acids and small residues are sufficient for generating high affinity antibodies (24, 25) . This strategy allows better sampling of the potential sequence space in a library of approximately 10 10 variants compared to randomizing with all 20 amino acids.
The library of GB1 mutants was screened against the chemically synthesized D-VEGF-A and after four rounds of panning 20-fold enrichment was observed by phage pool ELISA. Single clones were analyzed for binding-specificity ( Fig. 2A) , and then sequenced. SI Appendix, Table S1 shows the sequences of selected clones that bound to D-VEGF-A. SI Appendix, Fig. S2 shows the binding specificity of selected clones. Phage containing the clone RFX.T1.4 had the highest affinity for D-VEGF-A as determined by competitive ELISA. RFX.T1.4 phage bound specifically to D-VEGF-A ( Fig. 2A) , and the binding could be competed by the mirror image form of a known antagonistic peptide v114 (Fig. 2B ) (26) , suggesting that the GB1 mutants encoded by these clones would be likely to have antagonistic activity. Further affinity maturation was performed on clone RFX.T1.4, by relaxing codon constraints to allow all 20 amino acids at each of the randomized positions. Four libraries, each mutating a set of four residues (Fig. 2C) , were constructed and three rounds of phage selections were performed. Twenty-four clones were selected and sequenced from each library, and from the unique sequences a binding profile was generated as shown in Fig. 2D . The binding profiles indicated that hydrophobic residues were preferred at positions 22, 23, and 40 and were conserved at positions 26, 30, and 37. Negatively charged residues were conserved in positions 27 and 42. Of the 16 randomized residues, these eight residues seemed to be important for binding to D-VEGF-A. From the binding profiles it appeared that the dominant mutations obtained from affinity maturation were Y23F and F40I. Preliminary experiments showed that only the Y23F mutation increased the affinity (twofold), while the F40I mutation did not improve affinity. Therefore a point mutant [Y23F]RFX.T1.4 was constructed and phage containing this point mutant had high affinity for D-VEGF-A. A GB1-derived protein molecule with this amino acid sequence (RFX001) was chosen for further study (Fig. 2E ).
Chiral Specificity of VEGF-A Interactions with Mirror Image RFX001
Protein Ligands. The D-amino acid and L-amino acid forms of the RFX001 polypeptide chain were chemically synthesized and were each separately folded by dissolution in PBS at pH 7.4, and used to evaluate affinity for the enantiomeric forms of VEGF-A.
The mirror image RFX001 protein ligands showed reciprocal chiral specificity in surface plasmon resonance experiments as shown in Fig Table S2 ). The enantiomeric forms of the RFX001 protein molecule were also evaluated for their ability to inhibit the binding of VEGF 165 , the most abundant form of VEGF-A found in vivo (16) , to its receptor VEGFR1 (Flt1). Only D-RFX001 inhibited the binding of VEGF 165 to the VEGF receptor Flt1 (Fig. 3B) .
Structure of the fVEGF-A þ D-Protein Antagonistg Complex by Racemic Crystallography. We next set out to determine the molecular structure of the complex of VEGF-A with the protein antagonist D-RFX001. We attempted to crystallize a mixture of synthetic L-VEGF-A with two equivalents of synthetic D-RFX001 using 96 index conditions of the Quiagen Pro-complex suite; only two conditions produced micro crystals. Optimization of these two conditions did not lead to the formation of diffraction-quality crystals. Recently we showed that a racemic protein mixture crystallizes more readily than the natural L-protein alone*, and this has enabled us to use racemic crystallography to determine a number of . Underlined/bold residues are optimized in RFX001 compared to GB1; a residue was inserted between residues 41 and 42 as discussed in the text.
*Other potential advantages of racemic protein crystallography include: Facilitated crystallization to give well-ordered racemic crystals that diffract to high resolution; and, in the centrosymmetric space groups that can only be formed from a racemic mixture, phases of the reflections are quantized (e.g. for P1 hbari or P2 1 ∕c it is 0 or π radians), which can simplify structure solution (2, 5, 32).
protein structures that had not previously been determined by X-ray crystallography (3, 4, 7) . However, to date racemic protein crystallography has not been used to determine the structure of a heterochiral protein complex; i.e., a complex that consists of two different protein molecules of opposite chirality that bind to one another in solution. Here, we obtained crystals from a solution of chemically synthesized protein molecules that contained one equivalent each of L-VEGF-A and D-VEGF-A, and two equivalents each of the enantiomeric forms of the protein antagonist; i.e., D-RFX001 and L-RFX001 † . Crystals were readily obtained, and synchrotron X-ray diffraction data were collected to 1.6 Å resolution. Data reduction statistics revealed that the protein complex had crystallized in the centrosymmetric space group P2 1 ∕n. Matthews cell content analysis (27) suggested that there were one VEGF-A protein molecule and two RFX001 protein molecules in the P2 1 ∕n asymmetric unit. The structure was solved in P2 1 ∕n by molecular replacement using inverted and noninverted coordinates of the previously reported crystal structures of VEGF (PDB code: 3QTK) and GB1 (PDB code: 2QMT), as shown in Fig. 4 .
The Binding Interface. Each L-VEGF-A protein molecule bound two D-RFX001 protein molecules. The structure of the VEGF protein molecule in the fVEGF-A þ D-RFX001g complex is closely similar to that found in previously reported structures (17, 18) . The structure of RFX001 in comparison to wild-type GB1 (PDB code: 2QMT) revealed that the major differences in the structure occur in the loop 2 region which has one amino acid inserted between residues 41 and 42 of the wild-type sequence. The Cα atoms in the rest of the two proteins align with a rmsd of 0.75 Å. Note that Phe37 and Phe40 in loop 2 form part of the RFX001 protein core and help order loop 2 to present a suitable surface for VEGF-A binding (SI Appendix, Fig. S5 ). Apart from the mutated residues, the side chains of the residues in the RFX001 molecule align well with those of GB1, except for Trp42
It is of particular note that D-RFX001 binds to the same region of VEGF-A that interacts with VEGFR1-domain 2 (17), consistent with the ability of D-RFX001 to act as an antagonist of the VEGF-A/VEGFR1 interaction. The structural basis for this antagonism is vividly illustrated in Fig. 5 (top) . Despite its modest size, the protein D-RFX001 exhibits a contact surface area of approximately 800 Å 2 at the binding interface with VEGF-A and covers much of the contact surface that VEGF-A uses to interact with domain 2 of the VEGFR1 receptor molecule (17) .
The interaction between the two protein molecules is dominated by a total of ten aromatic residues (six from D-RFX001 and four from the VEGF-A molecule) (Fig. 5, bottom, left) . In the D-RFX001 ligand the helix (α1), the third β-strand (β3), and the loop spanning residues 37 to 41 all participate in contacts with VEGF-A. (Fig. 5, bottom, middle) . There are several other D-RFX001-VEGF-A hydrogen bonding networks mediated by well defined water molecules as shown in Fig. 5 , bottom, right.
Comparison of Protein Enantiomers. In order to compare the enantiomeric forms of the proteins present in the unit cell, we also solved the structure in the space group P2 1 ‡ . This procedure allows the enantiomeric protein molecules present in the complex to vary independently of one another in optimizing the fit of the molecular structures to the experimental electron densities. The P2 1 asymmetric unit contained a total of six synthetic protein molecules: Two D-RFX001 protein molecules bound to the opposite poles of one L-VEGF-A molecule; and, two L-RFX001 protein molecules bound to the opposite poles of one D-VEGF-A molecule (Fig. 4B) . Because the complex crystallized in the centrosymmetric monoclinic space group P21∕n, it possesses an inversion center. Comparison of the coordinates of main chain nonhydrogen atoms between enantiomeric VEGF-A molecules which are related by inversion gave an rmsd value of 0.2 Å. Comparisons between enantiomers for the four RFX001 protein molecules found in the P2 1 asymmetric unit are more complicated: Two enantiomeric pairs are related by inversion (L1-D2 or L2-D1 in Fig. 6 ), and two enantiomeric pairs are NOT related by inversion (L1-D1 or L2-D2 in Fig. 6 ). Comparison of pairs of enantiomeric RFX001 protein molecules that are related by inversion gave a main chain rmsd value of just 0.1 Å. Comparison of pairs of enantiomers that are NOT related by inversion gave a main chain rmsd value of 0.5 Å; this larger value is not unexpected, because in this case the enantiomers are in distinct environments within the crystal.
Conclusions
Total chemical synthesis of the mirror image form of VEGF-A has enabled the identification of an engineered protein ligand with high affinity and specificity for the D-VEGF-A protein molecule. The small protein GB1 was used as a unique scaffold to display a designed diversity library of mutants. Screening against D-VEGF-A, followed by a round of affinity maturation, identified mutants with good affinity and enabled the design of a point mutant with high affinity for D-VEGF-A. Chemical synthesis of the mirror image form of the point mutant gave a D-protein ligand that bound to L-VEGF-A but as expected did not bind to D-VEGF-A. The D-protein ligand acted as an antagonist of natural VEGF binding to its cognate receptor Flt1. The high resolution X-ray structure of the heterochiral {L-VEGF-A + D-protein antagonist} was determined by racemic protein crystallography. Detailed analysis of the interaction between the D-protein antagonist and VEGF-A showed that the binding interface comprised a contact surface area of approximately 800 Å 2 in accord with our design objectives, and that the D-protein antagonist binds to the same region of VEGF-A that interacts with VEGFR1-domain 2.
Using the D-protein ligand designed by phage display and the corresponding L-protein target molecule, we have shown that the determination of the high resolution X-ray structures of even large protein complexes can be facilitated by racemic crystallography. Experimentally, this work involved the total chemical synthesis of the enantiomeric forms of protein molecules of 6.4 kDa and 23.8 kDa. Crystallization of a racemic mixture of these synthetic proteins in appropriate stoichiometry gave a racemic protein complex of more than 73 kDa containing six synthetic protein molecules. The structure shown in Fig. 4 is the first example of a new class of protein complex, one consisting of two Solving a structure in the centrosymmetric space group P2 1 ∕n involves a mathematical inversion that averages the electron densities of the protein enantiomers, and thus obscures any potential differences that may exist.
protein molecules of different amino acid sequence and with opposite chiralities that specifically interact with one another. Based on the principles of stereochemistry and associated nomenclature, we have termed this class a 'heterochiral protein complex' (28). We believe that this work illustrates the great potential of a systematic chemical protein synthesis plus protein phage display approach to the development of D-proteins as a previously unexplored class of molecules for antagonizing the action of natural protein molecules. Such D-protein antagonists may have significant advantages as human therapeutics. Phage Display. The gene encoding the wild-type streptococcal protein GB1 domain sequence (22) was cloned into a display vector as N-terminal fusion to truncated protein 3 of M13 filamentous phage. A subset of 15 contiguous solvent exposed residues was chosen for randomization. Oligonucleotides with degenerate codon KHT (encoding Y, A, D, S, F, V) were used to construct a library of 8 × 10 9 transformants by previously described protocols (29, 30) . Four rounds of selection against D-VEGFA were carried out following essentially the same protocols previously described (30) . Because limited diversity (Y, A, D, S, F, V) was used in the initial library, we prepared affinity maturation libraries to allow all 20 amino acids to occur at each randomized position. A library of 1 × 10 9 transformants was obtained and selections were performed as described in the SI Appendix.
Racemic Protein Crystallography. The heterochiral protein complex was crystallized from the racemic mixture using 1∶2 stoichiometry of protein∶ligand. Diffraction data sets were collected to a resolution of 1.6 Å at the Advanced Photon Source, Argonne National Laboratory. The structures were solved by molecular replacement with the program PHASER (31) using the inverted and noninverted coordinates of previously reported X-ray structures of synthetic L-VEGF(8-109) (PDB code 3QTK) and GB1 (PDB code 2QMT) as search models. Full details are given in the SI Appendix.
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Reverse phase HPLC and LC-MS analysis
Analytical reverse phase HPLC reported in this work was performed on an in--house packed C--4 (Microsorb, 3 μm, 300 Å), 2.1 x 50 mm silica column at a flow rate of 0.5 mL/min or an Agilent C--3 (3.5 μm, 300 Å) 4.6 x150 mm silica column at a flow rate of 1 mL/min using a linear gradient of 10--54% of buffer B in buffer A over 22 min or 5--65% of buffer B in buffer A over 60 min at 40 °C (buffer A= 0.1% TFA in H2O; buffer B = 0.08% TFA in acetonitrile). The absorbance of the column eluate was monitored at 214 nm. The peptide masses were measured by on--line LC--MS using an Agilent 1100 LC/MSD ion trap. Calculated masses were based on average isotope composition, unless otherwise stated. Preparative reverse phase HPLC of crude peptides was performed with an Agilent 1100 prep system on in--house packed C--18 or C--4 (10 μm, 300 Å), 10 x 250 mm columns at 40 °C using an appropriate shallow gradient of increasing concentration of buffer B in buffer A at a flow rate of 5 mL/min. Fractions containing the purified target peptide were identified by MALDI time--of--flight MS, and aliquots from each selected fraction were combined and checked by LC--MS. Selected fractions were then combined and lyophilized. 1. Total chemical synthesis of D-VEGF-A 1.1 Peptide synthesis/purification/LCMS characterization. Peptide segments were synthesized using manual 'in situ neutralization' Boc chemistry protocols for stepwise SPPS 38 . After removal of the N--α Boc group, peptides were cleaved from the resin and simultaneously deprotected by treatment at 0 °C for 1 h with anhydrous HF containing 5%v/v p--cresol as scavenger. After removal of HF by evaporation under reduced pressure, each crude peptide was precipitated and washed with diethyl ether, then dissolved in 50% aqueous acetonitrile containing 0.1% TFA and lyophilized. The C--terminal peptide segment and peptide thioester segments of the D--VEGF--A were prepared following the same procedure as described for the L--VEGF--A synthesis 19 . Preparative HPLC purification gave the following amounts of each peptide segment: 70 mg (12 μmol, 6% yield from 0. The electrospray ionization mass spectrum of the synthetic VEGF protein was acquired by direct infusion on an Agilent 1100 LC/MSD ion trap using a 30 μM concentration of synthetic protein dissolved in 80% aqueous methanol containing 1% acetic acid (v/v). The solution was infused into the ion source at a flow rate of 2 μL/min using a syringe pump. Dry nitrogen was heated to 250 °C and introduced into the capillary region at a flow rate of 3 L/min. Compound stability and trap drive level parameters were adjusted to 25% and 70% respectively. HPLC and direct infusion ESMS data for the folded, homodimeric synthetic D-VEGF--A protein is shown in Figure 1C ; observed mass: 23849.3±0.7 (average of the two most abundant charge states); calculated mass: 23849.1 Da (average isotopes).
Circular Dichroism (CD).
The circular dichroism spectrum of the synthetic D--VEGF--A protein was recorded on an AVIV--202 instrument. An aqueous solution of synthetic D--VEGF--A (15 µM, 358 µg/mL) was transferred to a CD cuvette of path length 0.1 cm. CD spectra were measured at room temperature over the range 190--250 nm using 1 nm step and averaging of 5 scans. CD data is shown in Figure S1B .
Phage Display of GB1 2.1 Cloning
The gene encoding the wild--type streptococcal protein G B1 domain sequence 22 was ordered for synthesis from Genscript USA Inc. This sequence was synthesized with NcoI and XbaI restriction sites at 5' and 3' respectively and cloned into a display vector as N--terminal fusion to truncated protein 3 of M13 filamentous phage. The complete ORF of the display construct is shown below.
The salient features include a N--terminal FLAG tag and C--terminal dimerization sequence derived for human IgG1. The fusion protein is expressed under the control of ptac promoter.
Library design and construction
The solvent accessible surface area (SASA) for each residue in the structure PDB 3GB1 was estimated using the GetArea tool. The tool also calculates the ratio of SASA in structure compared to SASA in a random coil. An arbitrary cutoff ratio of 0.4 was used to differentiate the solvent accessible residues from buried residues. The solvent exposed residues are shown in bold and red below TYKLILNGKTLKGETTTEAVDAATAEKVFKQYANDNGVDGEWTYDDATKTFTVTE A subset of 15 contiguous solvent exposed residues (based on GB1--Fc binding interface) was chosen for randomization. Preliminary experiments (unpublished results) demonstrate that GB1 tolerates insertions of one or two amino acids in the loop (residues 37--41). Therefore these insertions were allowed in the randomization scheme shown below. Oligonucleotides with degenerate codon KHT (encoding Y,A,D,S,F,V) were ordered from Integrated DNA Technologies Inc.,USA. The sequences are shown below These oligonucleotides include a 15bp homology region (underlined) at 5' and 3'ends to facilitate site--directed mutagenesis. The libraries were constructed by previously described protocols 33,34 and library of 8 x 10 9 transformants was obtained. 
Phage panning
The selection procedure is essentially the same as mentioned in previous protocols 34 with some minor changes. Briefly, D--VEGFA was adsorbed on 96 well Maxisorp plate (Thermo Fisher) at concentration of 5µg/ml. For Round 1 and Round 2 of panning, the library/phage pool was preincubated on Glutathione S--transferase (GST) coated Maxisorp plates (10µg/ml) to clear non--specific binders prior to binding to D--VEGFA. Bound phage was washed and eluted with 100mM HCl and neutralized with 1M Tris--HCl, pH 11. The eluted phage was amplified in e.coli XL1--blue cells with use of M13K07 helper phage (New England Biolabs). For Rounds 3 and 4, the phage pools were pre--incubated with 0.2 mg/ml GST in solution for 1 hr before transfer to selection wells. The enrichment of the phage was monitored by phage pool ELISA using anti--M13--HRP conjugate (GE Healthcare) antibody and the data is shown in Figure S2A . Figure  S2B . 2.4 Binding epitope mapping of RFX.T1. 4 Fairbrother et. al. 26 developed antagonistic peptides that bind to VEGF--A at the same site as VEGFR1. The peptide v114 (VEPNCDIHVMWEWECFERL--NH 2 ) was ordered in both D and L forms from CSBio, Inc, USA. The following assay was used to determine whether the phage bound to the same epitope as v114. D--VEGFA coated on Maxisorp plate was preblocked with saturating concentration of v114 (100µM) for 30min at room temperature. In a control well, D--VEGFA was left unblocked with an equal volume of buffer. RFX.T1.4 phage (~1 x10 10 cfu/ml) was spiked into both the wells and allowed to bind for 1hr. The binding was estimated after washing using anti--M13--HRP conjugate antibody. Significant reduction of phage binding in the presence of peptide indicated that RFX.T1.4 binds to the same epitope as v114.
Affinity Maturation of RFX.T1.4
Because limited diversity (Y, A, D, S, F, V) was used in the initial library, we prepared affinity maturation libraries to allow all 20 aa to occur at each randomized position. The randomization scheme is shown in Figure 2C . The following oligonucleotides were used for site--directed mutagenesis. Table S2 . 
